SequelSEC

DNA X, Inc. SONM

Telephone & Telegraph Apparatus · CIK 0001178697 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$16.21M
Fiscal year ended 2025-09-30
Operating income
-$3.98M
Fiscal year ended 2025-09-30
Free cash flow
Unavailable
Fiscal year ended 2025-09-30

DNA X, Inc. (SONM) reported revenue of $16.21M and net income of -$4.75M for the fiscal year ended 2025-09-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from DNA X, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Telephone & Telegraph Apparatus.

Income

DNA X, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-30
Revenue$16.21M$11.19M$16.72M$14.98M$15.02MUnavailableUnavailable$13.43M$27.57M$26.84M
Cost of revenue$14.40M$10.34M$8.36M$15.17M$10.79MUnavailableUnavailable$8.31M$21.96M$22.41M
Gross profit$1.82M$845.00K$8.36M-$183.00K$4.23MUnavailableUnavailable$5.12M$5.60M$4.43M
Operating income-$3.98M-$1.47M-$870.00K$8.44M-$2.38MUnavailableUnavailable-$1.26M$688.00K$747.00K
Net income-$4.75M-$7.48M$458.00K-$21.61M-$2.51MUnavailableUnavailable-$1.35M$527.00K$509.00K
Research & development$181.00K$909.00K$1.63M$12.51M$715.00KUnavailableUnavailable$926.00K$741.00K$0
Weighted-average diluted sharesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableshares 4.42Mshares 4.46M
Pretax income-$4.66M-$1.86M-$961.00K$8.87M-$2.40MUnavailableUnavailable-$1.26M$623.00K$581.00K
Income tax expense$90.00K$138.00K$132.00K-$53.00K$117.00KUnavailableUnavailable$93.00K$96.00K$72.00K
Diluted EPS$-4.83$-14.15$1.41Unavailable$-9.32UnavailableUnavailableUnavailable$0.12$0.11
Selling, general & administrative$5.62MUnavailableUnavailableUnavailable$5.89MUnavailableUnavailable$5.45M$4.17M$3.68M
General & administrative$3.16M$1.47M$870.00K-$4.84M$2.85MUnavailableUnavailable$2.40M$2.04M$1.85M
Selling & marketing$2.45M$3.44M$3.24M$4.21M$3.04MUnavailableUnavailable$3.05M$2.13M$1.83M

Balance

DNA X, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-30
Cash & equivalents$2.14M$2.01M$2.12M$5.34M$9.06MUnavailableUnavailable$9.40M$9.80M$9.72M
Total assets$40.22M$36.08M$35.96M$39.74M$49.15MUnavailableUnavailable$56.04M$58.61M$53.74M
Current assets$30.30M$27.12M$26.94M$32.16M$33.86MUnavailableUnavailable$43.79M$47.54M$43.47M
Total liabilities$40.92M$37.41M$37.04M$45.44M$33.80MUnavailableUnavailable$33.68M$35.50M$32.09M
Current liabilities$38.86M$35.66M$34.68M$43.74M$32.18MUnavailableUnavailable$32.15M$34.04M$30.64M
Total equity incl. NCI-$701.00K-$1.33M-$1.08M-$5.70M$15.35MUnavailableUnavailable$22.37M$23.11M$21.65M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$10.99M$9.89M$8.62M$10.62M$12.37MUnavailableUnavailable$6.52M$4.22M$4.74M
Accounts receivable$3.50M$2.87M$4.85M$4.34M$5.24MUnavailableUnavailable$25.30M$30.35M$26.58M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$250.00K$2.92M$566.00KUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$20.41M$20.58M$17.29M$738.00K$9.06MUnavailableUnavailable$19.85M$23.26M$20.91M

Cash flow

DNA X, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-30
Operating cash flow-$7.03M-$4.88M-$9.61M-$4.51M-$417.00KUnavailableUnavailable-$351.00K-$304.00K$820.00K
Capital expendituresUnavailableUnavailableUnavailable$8.00K$137.00KUnavailableUnavailable$12.00K$1.00KUnavailable
Investing cash flowUnavailableUnavailableUnavailable-$8.00K-$137.00KUnavailableUnavailable-$12.00K-$1.00KUnavailable
Financing cash flow$7.16M$4.77M$6.38M$800.00K$14.00KUnavailableUnavailable-$37.00K$382.00K-$36.00K
Net change in cash$131.00K-$109.00K-$3.23M-$3.72M-$540.00KUnavailableUnavailable-$400.00K$77.00K$761.00K
Stock-based compensation$166.00K$926.00K$290.00K$356.00K$373.00KUnavailableUnavailable$458.00K$371.00K$358.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$952.00K$797.00K$1.06M$914.00K$918.00KUnavailableUnavailable$956.00K$67.00K$553.00K

Derived

DNA X, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-30
Free cash flowUnavailableUnavailableUnavailable-$4.52M-$554.00KUnavailableUnavailable-$363.00K-$305.00KUnavailable
Gross margin11.2%7.6%50.0%-1.2%28.2%UnavailableUnavailable38.1%20.3%16.5%
Operating margin-24.5%UnavailableUnavailableUnavailable-15.8%UnavailableUnavailable-9.3%2.5%2.8%
FCF marginUnavailableUnavailableUnavailable-30.1%-3.7%UnavailableUnavailable-2.7%-1.1%Unavailable
SBC / revenue1.0%UnavailableUnavailableUnavailable2.5%UnavailableUnavailable3.4%1.3%1.3%
Current ratio0.78x0.76x0.78x0.74x1.05xUnavailableUnavailable1.36x1.40x1.42x
Revenue YoY growth7.9%UnavailableUnavailable11.6%-45.5%UnavailableUnavailable-44.3%34.5%124.5%
Net margin-29.3%UnavailableUnavailableUnavailable-16.7%UnavailableUnavailable-10.1%1.9%1.9%
R&D / revenue1.1%8.1%9.8%83.5%4.8%UnavailableUnavailable6.9%2.7%0.0%
CapEx / revenueUnavailableUnavailableUnavailableUnavailable0.9%UnavailableUnavailable0.1%0.0%Unavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable-0.6%UnavailableUnavailableUnavailableUnavailable15.4%12.4%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SONM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-19View SEC filing
10-Q · Filed 2026-05-20View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-10-31View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

Reconciliation checks needing review

4 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2024-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.